947583-96-2Relevant academic research and scientific papers
NIPECOTIC ACID DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
-
, (2015/03/03)
The present invention aims to provide a compound having an sEH-inhibiting activity and to provide a pharmaceutical having a therapeutic effect and a prophylactic effect on chronic renal disease and pulmonary hypertension based on the sEH-inhibiting action. The present invention provides nipecotic acid derivatives represented by the chemical formula below and pharmaceutically acceptable salts thereof.
Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase
Thalji, Reema K.,McAtee, Jeff J.,Belyanskaya, Svetlana,Brandt, Martin,Brown, Gregory D.,Costell, Melissa H.,Ding, Yun,Dodson, Jason W.,Eisennagel, Steve H.,Fries, Rusty E.,Gross, Jeffrey W.,Harpel, Mark R.,Holt, Dennis A.,Israel, David I.,Jolivette, Larry J.,Krosky, Daniel,Li, Hu,Lu, Quinn,Mandichak, Tracy,Roethke, Theresa,Schnackenberg, Christine G.,Schwartz, Benjamin,Shewchuk, Lisa M.,Xie, Wensheng,Behm, David J.,Douglas, Stephen A.,Shaw, Ami L.,Marino Jr., Joseph P.
supporting information, p. 3584 - 3588 (2013/07/19)
1-(1,3,5-Triazin-yl)piperidine-4-carboxamide inhibitors of soluble epoxide hydrolase were identified from high through-put screening using encoded library technology. The triazine heterocycle proved to be a critical functional group, essential for high potency and P450 selectivity. Phenyl group substitution was important for reducing clearance, and establishing good oral exposure. Based on this lead optimization work, 1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N- {[[4-bromo-2-(trifluoromethoxy)]-phenyl]methyl}-4-piperidinecarboxamide (27) was identified as a useful tool compound for in vivo investigation. Robust effects on a serum biomarker, 9, 10-epoxyoctadec-12(Z)-enoic acid (the epoxide derived from linoleic acid) were observed, which provided evidence of robust in vivo target engagement and the suitability of 27 as a tool compound for study in various disease models.
Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase
Taylor, Steven J.,Soleymanzadeh, Fariba,Eldrup, Anne B.,Farrow, Neil A.,Muegge, Ingo,Kukulka, Alison,Kabcenell, Alisa K.,Lombaert, Stephane De
scheme or table, p. 5864 - 5868 (2010/08/03)
A series of potent nicotinamide inhibitors of soluble epoxides hydrolase (sEH) is disclosed. This series was designed using structure-based deconstruction and a combination of two HTS hit series, resulting in hybrid analogs that retained the optimal poten
NOVEL SEH INHIBITORS AND THEIR USE
-
Page/Page column 36-37, (2009/05/28)
The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
SUBSTITUTED PYRIDINEAMIDE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS
-
Page/Page column 80, (2008/06/13)
Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.
